Mereo BioPharma Group plc (Mereo) (MREO): Price and Financial Metrics
GET POWR RATINGS... FREE!
MREO Stock Price Chart Interactive Chart >
MREO Price/Volume Stats
|Current price||$0.53||52-week high||$3.75|
|Prev. close||$0.49||52-week low||$0.30|
|Day high||$0.57||Avg. volume||819,556|
|50-day MA||$0.87||Dividend yield||N/A|
|200-day MA||$1.66||Market Cap||62.34M|
Mereo BioPharma Group plc (Mereo) (MREO) Company Bio
Mereo BioPharma Group plc (Mereo) operates as a clinical stage biopharmaceutical company. The Company develops medicines for rare and specialty diseases. Mereo serves the healthcare sector globally.
Most Popular Stories View All
MREO Latest News Stream
|Loading, please wait...|
MREO Latest Social Stream
View Full MREO Social Stream
Latest MREO News From Around the Web
Below are the latest news stories about Mereo Biopharma Group plc that investors may wish to consider to help them evaluate MREO as an investment opportunity.
In this article you are going to find out whether hedge funds think Mereo BioPharma Group plc (NASDAQ:MREO) is a good investment right now.
A UAB investigated covid treatment from Mereo BioPharma Group shows positive results in early clinical trial.
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Mereo Biopharma Group Plc (MREO)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report) with bullish sentiments. Merck & Company (MRK) In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $100.00. The company's shares closed last Wednesday at $76.05. According to TipRanks.
Mereo BioPharma Group plc (NASDAQ:MREO) traded at $1.60 at last check on Wednesday, December 22, made a downward move of -3.03% on its previous days price. Looking at the stock we see that its previous close was $1.65 and the beta (5Y monthly) reads 1.49 with the days price range being $1.62 $1.70. In Investors Take Advantage Of -3.03% Loss In Mereo BioPharma Group plc (NASDAQ: MREO) Read More »
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus standard of care LONDON and REDWOOD CITY, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat,
MREO Price Returns